GSK’s HIV Unit, ViiV Healthcare, Helping Spur Growth In Company

Financial Times: HIV unit emerges as ‘critical’ driver of GSK growth
“It is only a year since GlaxoSmithKline was considering a spin-off of its HIV unit as a way to unlock value for disgruntled shareholders. The option was rejected and now the business, known as ViiV Healthcare, is playing an increasingly important role in efforts to return the U.K. drugmaker to growth…” (Ward, 2/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.